{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 79 of 129', 'For all countries except the US, all SAEs which are assessed as causally related to the IMP(s)', 'by either the investigator or LEO (ICH E2A Guideline), and which are unexpected', '(Suspected, Unexpected Serious Adverse Reactions [SUSARs]), are subject to expedited', 'reporting to regulatory authorities and IRB(s)/IEC(s) according to the current applicable', 'legislation in the concerned countries. Investigators will be notified of such SUSARs and the', 'evolving safety profile on an ongoing basis.', 'For the US, as per Guidance for Industry and Investigators - Safety Reporting Requirements', 'for INDs and BA/BE Studies, only those events for which the sponsor determines there is a', 'reasonable possibility of a causal relationship are subject to IND Safety Reporting.', 'Investigators will be notified of the evolving safety profile on an ongoing basis.', '11.4 Other events that require expedited reporting', '11.4.1 Pregnancy', 'Any pregnancy occurring during the clinical trial must be reported to LEO within 24 hours of', 'first knowledge using the (paper) Pregnancy Follow Up Form (Part I). All such pregnancies', 'must be followed up until delivery or termination and final outcome must be reported on the', '(paper) Pregnancy Follow Up Form (Part II) within 24 hours of first knowledge.', 'The completed Pregnancy Follow Up Forms must be faxed or scanned and e-mailed to Global', 'Pharmacovigilance, LEO. Contact details are given in Section 11.3.1.', 'Pregnant subjects must permanently discontinue IMP (see Section 9.7.1).', '11.5 Reporting of other events', '11.5.1 Adverse events of special interest', 'The events listed in Panel 10 are considered adverse events of special interest (AESIs) in this', 'trial and will require that the investigator provides additional information to LEO. An AESI', 'may be serious (requiring expedited reporting, Section 11.3) or non-serious.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 80 of 129', 'Panel 10 Adverse events of special interest', 'Adverse event of special interest', 'Additional information to be provided (if available\u00b9)', 'Skin findings:', 'Lesion type.', 'Disseminated / localised.', 'Location.', 'Eczema herpeticum', 'Present in an area with visible eczema / no visible', 'eczema / present in areas with and without eczema.', 'Monomorphic / polymorphic.', 'Confirmation of herpes simplex virus.', 'Malignancies diagnosed after', 'Histology report.', 'randomisation, excluding basal', 'Oncology assessment.', 'cell carcinoma, localised squamous', 'Treatments (surgery, radiation, chemotherapy, other).', 'cell carcinoma of the skin, and', 'carcinoma in situ of the cervix', 'Skin infections requiring systemic', 'Skin swab', 'treatment', 'Outcome.', 'Aetiology (viral, bacterial, allergic, unknown).', 'Bacterial culture outcome (for events with bacterial', 'Conjunctivitis', 'aetiology).', 'Diagnosis confirmed by ophthalmologist.', 'Aetiology (infectious, non-infectious, other,', 'unknown).', 'Keratoconjunctivitis', 'Bacterial culture outcome (for events with bacterial', 'aetiology).', 'Diagnosis confirmed by ophthalmologist.', 'Aetiology (infectious, non-infectious, other,', 'unknown).', 'Bacterial culture outcome (for events with bacterial', 'Keratitis', 'aetiology).', 'Diagnosis of herpes simplex keratitis (for events with', 'viral aetiology).', 'Diagnosis confirmed by ophthalmologist.', '1', 'The additional data to be recorded in the eCRF are not a requirement, but are to be reported', 'by the investigator, if available, for example as part of standard clinical practice.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 81 of 129', '11.5.2 Overdose', 'An overdose is defined as a subject receiving a dose of IMP in excess of that specified in this', 'protocol.', 'The term overdose must be documented on the AE form of the eCRF. In addition, AEs', 'originating from overdose must be documented on a separate line.', 'LEO does not recommend specific treatment for an overdose. The investigator will use', 'clinical judgment to treat any overdose if necessary.', '11.5.3 Medication error', 'Medication error refers to any unintentional error in the dispensing or administration of an', 'IMP while in the control of the investigator or subject. Broadly, medication errors fall into', 'four categories: wrong medication, wrong dose (including strength, form, concentration,', 'amount), wrong route of administration, or wrong subject.', 'The medication error must be documented on the AE form in the eCRF. In addition, AEs', 'originating from a medication error must be documented on a separate line specifying the', 'category of error (see definitions above).', 'If the medication error is due to device malfunction, such malfunction must be reported as a', 'device complaint as described in Section 9.10.', '11.5.4 Misuse', 'Misuse refers to situations where the IMP is intentionally and inappropriately used not in', 'accordance with the protocol.', 'The term misuse must be documented on the AE form in the eCRF. In addition, AEs', 'originating from misuse must be documented on a separate line.', '11.5.5 Abuse', 'Abuse relates to the sporadic or persistent, intentional excessive use of an IMP which is', 'accompanied by harmful physical or psychological effects.', 'The term abuse must be documented on the AE form in the eCRF. In addition, AEs', 'originating from abuse must be documented on a separate line.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}